Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) is 4.22% higher on its value in year-to-date trading and has touched a low of $15.32 and a high of $43.81 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ARCT stock was last observed hovering at around $32.13 in the last trading session, with the day’s gains setting it 0.73%.
Currently trading at $32.86, the stock is -9.58% and -8.86% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.87 million and changing 2.27% at the moment leaves the stock 10.86% off its SMA200. ARCT registered 107.32% gain for a year compared to 6-month gain of 22.93%. The firm has a 50-day simple moving average (SMA 50) of $3.94 and a 200-day simple moving average (SMA200) of -$25.73.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -23.56% loss in the last 1 month and extending the period to 3 months gives it a 0.18%, and is -0.87% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.08% over the week and 6.20% over the month.
Arcturus Therapeutics Holdings Inc (ARCT) has around 180 employees, a market worth around $884.59M and $160.88M in sales. Fwd P/E is 215.24. Profit margin for the company is -16.53%. Distance from 52-week low is 114.49% and -24.99% from its 52-week high. The company has generated returns on investments over the last 12 months (-8.73%).
Arcturus Therapeutics Holdings Inc quarterly earnings per share for the current quarter are estimated at -$1.05 with sales reaching $21.32M over the same period.The EPS is expected to shrink by -147.60% this year, but quarterly earnings will post -11.50% year-over-year. Quarterly sales are estimated to shrink -73.30% in year-over-year returns.
254 institutions hold shares in Arcturus Therapeutics Holdings Inc (ARCT), with institutional investors hold 100.89% of the company’s shares. The shares outstanding are 26.83M, and float is at 24.53M with Short Float at 17.15%. Institutions hold 92.00% of the Float.
The top institutional shareholder in the company is Federated Hermes, Inc. with over 4.78 million shares valued at $137.05 million. The investor’s holdings represent 17.97% of the ARCT Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 1.99 million shares valued at $57.14 million to account for 7.49% of the shares outstanding. The other top investors are State Street Corporation which holds 1.98 million shares representing 7.46% and valued at over $56.91 million, while ARK Investment Management, LLC holds 7.15% of the shares totaling 1.9 million with a market value of $48.58 million.
Arcturus Therapeutics Holdings Inc (ARCT) Insider Activity
The most recent transaction is an insider sale by Chivukula Pad, the company’s Chief Scientific Officer & COO. SEC filings show that Chivukula Pad sold 17,435 shares of the company’s common stock on Mar 25 ’24 at a price of $35.02 per share for a total of $0.61 million. Following the sale, the insider now owns 0.47 million shares.
Arcturus Therapeutics Holdings Inc disclosed in a document filed with the SEC on Mar 19 ’24 that Chivukula Pad (Chief Scientific Officer & COO) sold a total of 8,565 shares of the company’s common stock. The trade occurred on Mar 19 ’24 and was made at $35.01 per share for $0.3 million. Following the transaction, the insider now directly holds 0.49 million shares of the ARCT stock.
Still, SEC filings show that on Nov 01 ’23, Chivukula Pad (Chief Scientific Officer & COO) disposed off 5,000 shares at an average price of $18.72 for $93602.0. The insider now directly holds 499,448 shares of Arcturus Therapeutics Holdings Inc (ARCT).
